Supreme Court Eliminates Key Avenue for Suing Pesticide Manufacturers Over Cancer Risks

Last week, in the landmark case of Monsanto v. Durnell, the Supreme Court of the United States issued a decision that fundamentally altered the landscape of product liability law, specifically eliminating the long-established right of individuals to hold pesticide companies accountable in state courts for failing to warn consumers about potential cancer risks or other diseases associated with their products. This 7-2 ruling has sent ripples through the legal community, public health advocacy groups, and the agricultural industry, drawing both praise from corporate interests and sharp criticism from consumer protection advocates.

The Supreme Court’s Landmark Decision and Federal Preemption

The Court’s majority sided with Monsanto, now a subsidiary of Bayer, holding that individuals who contract cancer from using a pesticide are "preempted," or prohibited, from suing manufacturers on the grounds of a pesticide maker’s failure to warn them of cancer risks. This prohibition applies if the Environmental Protection Agency (EPA) has not required a specific cancer warning in its approval of the pesticide. The decision hinges on the interpretation of the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA), the primary federal statute governing the registration, distribution, sale, and use of pesticides in the United States.

FIFRA, enacted in 1947 and significantly amended over the years, grants the EPA extensive authority to regulate pesticides, including approving product labels. The core of the Supreme Court’s decision rests on the argument that if the EPA has reviewed a pesticide and not mandated a cancer warning, state-level "failure to warn" claims are preempted by federal law. In essence, the Court determined that allowing state common-law claims based on a lack of warning, when the EPA has specifically approved the label without such a warning, would create a conflict with federal regulatory authority. Justices Gorsuch and Brown Jackson notably dissented, arguing that the majority’s interpretation of FIFRA was an inaccurate reading of the statute’s language and overlooked the nuances of state common law.

Background of the Litigation: The Roundup Saga

The Durnell case is emblematic of tens of thousands of similar cases filed in lower courts across the nation. These cases largely involve plaintiffs who claim that Monsanto’s flagship herbicide, Roundup, and its active ingredient, glyphosate, caused their non-Hodgkin lymphoma. Roundup was first introduced by Monsanto in 1974 and quickly became one of the most widely used herbicides globally due to its effectiveness and the advent of "Roundup Ready" genetically modified crops designed to withstand its application. For decades, Monsanto maintained that glyphosate was safe, a position largely echoed by the EPA.

However, scientific and public opinion began to shift significantly in 2015 when the International Agency for Research on Cancer (IARC), a specialized cancer agency of the World Health Organization (WHO), classified glyphosate as "probably carcinogenic to humans." This classification served as a catalyst, fueling a surge in lawsuits against Monsanto, alleging that the company failed to adequately warn users of the potential cancer risks. These "failure to warn" claims formed a foundational element of the plaintiffs’ legal strategy, resonating powerfully with juries who found it compelling that a company might withhold crucial health information.

In 2018, German pharmaceutical giant Bayer acquired Monsanto for approximately $63 billion, inheriting the vast legal liabilities associated with Roundup. Since then, Bayer has faced immense pressure and significant financial outlays to address the burgeoning litigation, paying billions in settlements even as it continued to defend the safety of glyphosate.

Industry and Advocacy Reactions

The Supreme Court’s decision was met with predictable reactions from both sides. Bayer immediately celebrated the ruling, viewing it as a critical step toward resolving the massive outstanding litigation. "Bayer is celebrating this ruling because the company believes that this will put an end to the lawsuits that are still outstanding," noted Carey Gillam, editor-in-chief at The New Lede and a prominent author who has extensively covered the Monsanto trials. "They believe that without the failure to warn claims, the lawsuits become much more difficult for the plaintiffs to prevail — and that plaintiffs are much more likely to settle and that people will be less likely to sue them in the future." Indeed, on the day of the ruling, Bayer’s stock saw a significant surge, reportedly climbing 17 percent, signaling investor confidence in the reduced legal risk.

Conversely, public health advocates and consumer protection groups expressed profound disappointment and concern. George Kimbrell, legal director at the Center for Food Safety (CFS), a leading legal nonprofit focused on food and agriculture issues, stated, "Overturning decades of well-settled law, the Supreme Court eliminated one way the public held pesticide corporations accountable for their products’ harms." The CFS had filed an amicus brief in the Durnell case, representing a diverse coalition of farmers, farmworkers, medical professionals, consumer protection advocates, and conservationists, all urging the Court to uphold consumer rights. Kimbrell emphasized that while the decision was "tragic," it also served as "a clarion, galvanizing call to continued action," urging Americans to demand that their representatives prioritize public health over corporate profit margins.

Impact on Current and Future Lawsuits

The ruling is poised to have a substantial and immediate impact on the thousands of pending Roundup lawsuits. "Failure to warn" claims were often the most straightforward and compelling arguments for juries, making it easier for plaintiffs to demonstrate corporate negligence. Gillam elaborated on this, explaining, "From what I’ve seen attending a lot of these trials and reading the transcripts and writing a book about this, the failure to warn claim is something that is foundational to much of this litigation. It’s easy for juries to understand." She pointed to the IARC classification and the simple question of why a company wouldn’t include a warning label, comparing it to tobacco warnings.

With this avenue now largely closed, plaintiffs’ attorneys will need to pivot their strategies. While other claims, such as design defect or negligence, may still be viable, they are often more technically complex and harder to prove to a jury. "There are a number of plaintiffs attorneys who say — we have lost failure to warn, but we still can sue on other grounds — that the company was negligent, they didn’t design their products properly — it’s more dangerous than can reasonably be expected," Gillam observed. However, she cautioned, "When you take that away and start arguing the technicalities of the design defect claim, it does whittle away at the ease with which juries understand these cases." This shift could increase the costs and risks associated with litigation for plaintiffs’ firms, potentially reducing their willingness to take on new cases. Legal experts suggest that the ruling will likely lead to more settlements, possibly at lower values, as plaintiffs face a more challenging path to trial victories.

The Complexities of Mass Tort Settlements

The Roundup litigation, involving an estimated 170,000 cases at its peak, has been a monumental undertaking. The vast majority of these cases have been resolved, with Bayer estimating that 50,000 to 60,000 claims may still be outstanding. The company has already paid over $11 billion in settlements and judgments, with some individual punitive damages reaching into the billions of dollars, though Bayer has also prevailed in some trials.

These mass tort cases are typically managed through a multi-district litigation (MDL) process, where individual cases are consolidated before a single judge for pretrial motions, discovery, and expert witness testimony, streamlining the process without merging the individual lawsuits themselves. When cases are ready for trial, they usually return to their original home courts. Judge Vince Chhabria in California has overseen the Roundup MDL since its inception.

However, alongside the MDL, a controversial class action settlement has been proposed, offering an additional $7.25 billion to resolve current and future claims. This class action is distinct from the MDL, aiming to group all individuals who have sued, wish to sue, or may develop cancer and sue in the future into one settlement pool with tiered payouts. This particular class action settlement has been widely criticized, including by Judge Chhabria, who famously called it a "filthy" deal, deeming it unfair to plaintiffs and disproportionately beneficial to the attorneys who negotiated it. "Many people look at it as sort of a sweetheart deal for the plaintiffs attorneys. The plaintiffs themselves are very likely to get maybe a few thousands dollars each," Gillam explained. The settlement, filed in Missouri, has received preliminary approval from a Missouri judge, bypassing Judge Chhabria’s jurisdiction.

The Supreme Court’s preemption ruling adds another layer of complexity to this already contentious class action. Plaintiffs and their attorneys who previously resisted opting into the class action must now re-evaluate their positions, factoring in the diminished strength of their "failure to warn" arguments. Bayer, for its part, has indicated it might walk away from the class action settlement if not enough plaintiffs agree to its terms, viewing it as a comprehensive way to put the bulk of the litigation behind them.

Legislative Efforts to Counter the Ruling

In response to the Supreme Court’s decision, legislative efforts are already underway to restore the ability of individuals to sue pesticide manufacturers. Senator Cory Booker has expressed intentions to introduce legislation that would effectively overturn the Supreme Court’s ruling, potentially by adding an amendment to the farm bill. Similarly, Congresswoman Chellie Pingree has already introduced legislation to amend FIFRA, explicitly stating that federal preemption does not exist for failure-to-warn claims in state tort law.

However, such legislative endeavors face an uphill battle. The agricultural industry wields significant lobbying power in Washington, D.C., making it challenging to pass legislation that could increase corporate liability. Despite this, a growing grassroots movement, including groups like the "Make America Healthy coalition" and "mad moms" advocating for safer products, promises to elevate this issue in upcoming elections, aiming to put pressure on representatives to prioritize public health over corporate interests.

Broader Implications for Corporate Accountability

Beyond the immediate impact on Roundup cases, the Monsanto v. Durnell decision carries broader implications for corporate accountability across various industries. It strengthens the argument for federal preemption in areas where federal agencies regulate product labeling, potentially shielding manufacturers of other federally regulated products (e.g., pharmaceuticals, medical devices) from state tort claims if their labels comply with federal standards. This raises concerns among consumer advocates about a potential erosion of state-level consumer protection laws and access to justice for individuals harmed by products. The ruling underscores the critical importance of robust federal regulatory oversight by agencies like the EPA, as their decisions on product labeling now carry even greater weight in determining corporate liability. If federal agencies fail to mandate warnings for known or probable risks, consumers may have limited recourse.

Looking Ahead: The Paraquat Parallel

The legal battles over agricultural chemicals are far from over. Gillam highlights the ongoing paraquat litigation as a significant parallel development. Paraquat, another widely used weedkiller, is the subject of a similar MDL, with plaintiffs alleging it causes Parkinson’s disease. While smaller and newer than the Roundup litigation, it appears to be following a similar trajectory.

However, the paraquat MDL, overseen by Judge Nancy Rosenstengel, has introduced its own set of controversies. Gillam noted that the judge is "trying to induce people to agree to a settlement with Syngenta that plaintiffs lawyers say is pitiful and is a terrible deal." Moreover, the judge is reportedly imposing unusual scrutiny on plaintiffs who refuse the settlement offer, requiring them to undergo additional depositions and meetings with a special master if they wish to proceed to trial. This judicial pressure to settle raises further questions about fairness in mass tort litigation and the balance between encouraging resolution and protecting plaintiffs’ rights to pursue their claims.

The Supreme Court’s ruling in Monsanto v. Durnell marks a pivotal moment in product liability law, shifting the burden of accountability and forcing a re-evaluation of legal strategies for both corporations and consumers. As legislative efforts emerge and new mass torts like the paraquat litigation unfold, the debate over federal versus state regulatory power and corporate responsibility will continue to be a defining feature of the American legal landscape.